Germany Updates Meningococcal, Shingles Vaccine Policy for 2026
Germany adopts new STIKO vaccination recommendations, shifting meningococcal protection to adolescents and expanding shingles eligibility for high-risk adults starting in 2026.
Month: December 2025
EU Finalizes Landmark Pharma Reform to Reset Access and Incentives
The EU reaches a landmark deal on pharmaceutical reform, reshaping regulatory exclusivity, supply obligations, generic entry, and incentives for priority antibiotics.
NeuroPulse Today’s Signals: Personalized Neuromodulation, Pediatric Imaging Wins, and Schizophrenia IP Resets
NeuroPulse: Today’s Three Signals The neurology sector delivered three distinct signals today, spanning device-led personalization, regulatory expansion in pediatric imaging, and strategic recalibration in neuropsychiatric drug development. Together, they highlight how execution, not novelty, is increasingly determining momentum across neuroscience. Signal One: Soin Neuroscience and BIOTRONIK Push Spinal Cord Stimulation Toward Personalization Soin Neuroscience and … Read more
BioMarin to Acquire Amicus for $4.8B in Rare Disease Deal
BioMarin will acquire Amicus Therapeutics for $4.8B in cash, adding Galafold and Pombiliti + Opfolda and accelerating rare-disease revenue growth.
NeuroPulse Daily Brief: December 20, 2025
In Today’s NeuroPulse, the neurology sector advanced across multiple fronts, with fresh capital flowing into mental health drug development, early clinical milestones reached in brain cancer and neurodegeneration, and regulators extending approvals that lower risk in pediatric imaging and neuromodulation. From nine-figure biotech launches and oversubscribed neurotech seed rounds to first-in-human dosing, personalized spinal cord … Read more
CMS Confirms 2026 Coverage for MTF’s AmnioBand, AlloPatch
CMS confirms Medicare coverage for MTF Biologics’ AmnioBand Membrane and AlloPatch Pliable under updated LCDs for diabetic foot and venous leg ulcers starting 2026.
Netherlands Moves to Cut Mental Health Wait Times for 2026
The Dutch Healthcare Institute prioritizes group therapy and preventive mental health care to reduce long wait times under its 2026–2028 appropriate care agenda.
BioStem Lands 2026 CMS Status Quo Coverage for Skin Grafts
CMS places BioStem’s VENDAJE products in a 12-month status quo category, preserving DFU and VLU reimbursement through 2026 while evidence review continues.
NeuroPulse Today’s Signals: Precision Regulation, RNA Partnerships, and Real-World Data Redefine Neuro Strategy
NeuroPulse: Today’s Three Signals The neurology and neurodegeneration landscape is converging around execution rather than exploration. Today’s signals show how late-stage regulatory precision, platform-driven RNA partnerships, and regulator-grade real-world evidence are reshaping the path from discovery to durable market access. Across ALS, Alzheimer’s disease, and RNA-based therapeutics, stakeholders are tightening alignment between data, infrastructure, and … Read more
ENvue’s UroShield Secures UK NHS Reimbursement
ENvue Medical’s UroShield Kit is added to the NHS Drug Tariff Part IX, enabling nationwide reimbursement and triggering early commercial orders in the UK.